文献速递结核与非结核分枝杆菌

定义耐药突变的卡介苗菌株:结核实验室质量控制新工具

Bacillus Calmette-Guérin strains with defined resistance mutations: a new tool for tuberculosis laboratory quality control.
PubMed 文献 · Clin Microbiol Infect · 2019-11-06

研究将耐药相关突变引入野生型卡介苗(BCG),构建7株单耐药减毒菌株,用微量肉汤稀释法测定MIC90,并评估GeneXpert与Genotype MTBDRplus对耐药突变的检出能力。结果显示突变可对应表型耐药,但两法对rpoB I491F及新型katG缺失突变分别判为敏感,提示工程化BCG可作安全质控试剂。

要点

  • 工程化单耐药BCG菌株可安全用于结核诊断与药敏试验的质控。
  • GeneXpert与MTBDRplus均将rpoB I491F判为利福平敏感,与预期SNP位置一致。
  • MTBDRplus将新型katG缺失突变判为异烟肼敏感,尽管表型耐药。

核心结论

  • 将耐药突变引入减毒BCG可获得单耐药菌株,作为结核诊断与药敏试验的安全质控试剂。

研究设计与样本

  • 研究构建7株单耐药BCG菌株,突变经双脱氧核苷酸测序确认,表型耐药以微量肉汤稀释法测定MIC90,并独立评估两种商业检测对耐药突变的检出能力。

主要发现

  • 面板涵盖rpoB(S450L、I491F)、katG(AA428缺失)、gyrA(D94G)、rpsL(K43R)和Rv0678c(S63R)突变。
  • 上述突变分别对应利福平MIC≥8 mg/L、异烟肼MIC≥8 mg/L、莫西沙星MIC 4 mg/L和链霉素MIC≥8 mg/L的表型耐药。
  • Rv0678c突变株对氯法齐明(MIC 4 mg/L)和贝达喹啉(MIC 1 mg/L)敏感性下降。
  • GeneXpert与Genotype MTBDRplus均将rpoB S450L判为利福平耐药、I491F判为利福平敏感。
  • MTBDRplus将新型katG缺失突变判为异烟肼敏感,尽管其表型耐药。

临床怎么用

  • 可将工程化单耐药BCG菌株用作结核诊断试剂与药敏试验的质控品,弥补耐药菌株质控的安全与可及性问题。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: Laboratory quality control (QC) is essential to assess the reliability of tuberculosis diagnostic testing. To provide safe QC reagents for the detection of drug-resistant Mycobacterium tuberculosis, we generated antibiotic-resistant mycobacterial strains of attenuated virulence (M. bovis bacillus Calmette-Guérin (BCG)). METHODS: Seven mono-resistant BCG strains were developed by introducing resistance-conferring mutations into wild-type BCG strains. Mutations were confirmed by dideoxynucleotide sequencing. Phenotypic resistance was quantified by microbroth dilution to determine the MIC90. The capacity of two commercial tests (GeneXpert TB/RIF and Genotype MTBDRplus) to detect resistance-conferring mutations was evaluated independently. RESULTS: Our panel included BCG strains with mutations in rpoB (S450L, I491F), katG (deletion at AA428), gyrA (D94G), rpsL (K43R) and Rv0678c (S63R). These mutations translated respectively into phenotypic resistance to rifampin (MIC ≥8 mg/L), isoniazid (MIC ≥8 mg/L), moxifloxacin (MIC 4 mg/L) and streptomycin (MIC ≥8 mg/L); the Rv0678c mutant showed decreased susceptibility to both clofazimine (MIC 4 mg/L) and bedaqualine (MIC 1 mg/L). GeneXpert (Cepheid) and Genotype MTBDRplus (Hain Lifesciences) both called the rpoB S450L strain rifampin-resistant and the I491F mutant rifampin-susceptible, as expected based on single nucleotide polymorphism positions. Likewise, MTBDRplus called the novel katG deletion mutant isoniazid susceptible despite phenotypic resistance. CONCLUSION: BCG strains engineered to be mono-resistant to anti-tuberculosis drugs can be used as safe QC reagents for tuberculosis diagnostics and drug susceptibility testing.

来源:Clin Microbiol Infect,查看原文。版权归原作者所有。

引用

  1. Danchuk SN, McIntosh F, Jamieson FB, et al. Bacillus Calmette-Guérin strains with defined resistance mutations: a new tool for tuberculosis laboratory quality control. Clin Microbiol Infect. 2019. PMID: 31705996. doi:10.1016/j.cmi.2019.10.033

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。